Nanjing First Hospital, Nanjing Medical University

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The effect of polyethylene glycol Losenatide on body fat, insulin resistance, weight, blood sugar, blood lipid, stomach volume and other factors in patients with type 2 diabetes through 12 week follow-up, and explore the factors affecting the efficacy, so as to provide more evidence-based medical basis for drug treatment and benefit patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Type 2 diabetes was diagnosed according to World Health Organization(WHO) classification or other locally applicable diagnostic criteria.

• At least 8 weeks of simple diet control and physical exercise before screening; Type 2 diabetes patients with stable hypoglycemic drug treatment and insufficient blood glucose control within 8 weeks before screening.

• HbA1c≥7.5%.

• Body mass index (BMI) \> 24kg /m2.

• Subjects agreed to maintain scientific diet and exercise habits throughout the study, regularly conduct self blood glucose monitoring (SMBG) and make records.

• Willing to sign the written informed consent and abide by the research protocol.

Locations
Other Locations
China
Jianhua Ma
RECRUITING
Nanjing
Contact Information
Primary
Jianhua Ma, Doctor
majianhua196503@126.com
+8618951670116
Time Frame
Start Date: 2022-06-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 480
Treatments
Experimental: Polyethylene Glycol Losenatide
Trearment for 12 weeks
Related Therapeutic Areas
Sponsors
Leads: Nanjing First Hospital, Nanjing Medical University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials